Lisocabtagene maraleucel (liso-cel) is an autologous CAR T-cell therapy targeting the CD19 antigen that was tested in the TRANSCEND FL study in patients with relapsed or refractory follicular lymphoma[1]. In the third line of treatment and beyond, liso-cel achieved an overall response rate of 97% and a complete response rate of 94%[1][2]. In high-risk second-line patients, an overall response rate of 96% was achieved, with all responding patients achieving a complete response[1]. Median duration of response was not reached at a median follow-up of 16.6 months, with 81.9% of responding patients having an ongoing response at 12 months[2]. Adverse effects were manageable—cytokine release syndrome occurred in 58% of patients, with only 1% having grade 3 or higher severity[1]. Neurological events occurred in 15% of patients, of which only 2% were grade 3 or higher [1]. These results support lisocabtagene maraleucel as a new treatment option for patients with relapsed or refractory follicular lymphoma, including high-risk second-line patients[1].